Table 2 The relationship between TSC22D3 expression and clinical parameters in 173 adult AML data from the “TCGA-AML NEJM 2013” dataset of the cBioportal database
Characteristics | Low expression of TSC22D3 | High expression of TSC22D3 | P-value | Statistical approach |
|---|---|---|---|---|
n | 86 | 87 | ||
Sex, n (%) | 0.9354 | Chi-square test | ||
Male | 46 (26.59%) | 46 (26.59%) | ||
Female | 40 (23.12%) | 41(23.70%) | ||
Race, n (%) | 0.6837 | Chi-square with Yates' correction test | ||
White | 66 (48.53%) | 62 (45.59%) | ||
Black | 3 (2.20%) | 5 (3.68%) | ||
Age, n (%) | 0.1430 | Chi-square test | ||
≤ 60 | 53 (30.64%) | 44(25.43%) | ||
> 60 | 33 (19.08%) | 43 (24.85%) | ||
WBC count(× 10^9/L), n (%) | < 0.0001 | Chi-square test | ||
≤ 20 | 59 (34.10%) | 32 (18.50%) | ||
> 20 | 27 (15.61%) | 55 (31.79%) | ||
PB blasts(%), n (%) | 0.1458 | Chi-square test | ||
< 20 | 40 (23.12%) | 31 (17.92%) | ||
≥ 20 | 46 (26.59%) | 56(32.37%) | ||
BM blasts(%), n(%) | 0.0272 | Chi-square test | ||
≤ 70 | 46 (26.59%) | 32 (18.50%) | ||
> 70 | 40 (23.12%) | 55 (31.79%) | ||
FAB classifications, n (%) | 0.0356 | Chi-square test | ||
M0 | 9 (5.26%) | 7 (4.10%) | ||
M1 | 16 (9.36%) | 28 (16.37%) | ||
M2 | 25 (14.62%) | 13 (7.60%) | ||
M3 | 11 (6.43%) | 5 (2.92%) | ||
M4 | 15 (8.77%) | 19 (11.11%) | ||
M5 | 6 (3.51%) | 12 (7.02%) | ||
M6 | 1 (0.59%) | 1 (0.59%) | ||
M7 | 3 (1.75%) | 0 (0%) | ||
Cytogenetics, n (%) | 0.3945 | Chi-square test | ||
Normal | 37(21.64%) | 43 (25.15%) | ||
Complex | 7 (4.09%) | 15(8.77%) | ||
t(15;17) | 10 (5.85%) | 5 (2.92%) | ||
t(8;21) | 5 (2.92%) | 2 (1.17%) | ||
t(9;22) | 2 (1.17%) | 1 (0.59%) | ||
inv(16) | 4 (2.34%) | 6 (3.51%) | ||
11q23 | 2 (1.17%) | 2 (1.17%) | ||
+ 8 | 5 (2.92%) | 3 (1.75%) | ||
− 7 | 1 (0.59%) | 3 (1.75%) | ||
+ 21 | 2 (1.17%) | 1 (0.59%) | ||
Other | 10 (5.85%) | 5 (2.92%) | ||
FLT3 mutation, n (%) | 0.2570 | Chi-square test | ||
Negative | 65 (37.57%) | 59 (34.10%) | ||
Positive | 21 (12.14%) | 28 (16.19%) | ||
NPM1 mutation, n (%) | 0.0465 | Chi-square test | ||
Negative | 68 (39.31%) | 57 (32.95%) | ||
Positive | 18(10.40%) | 30 (17.34%) | ||
DNMT3A mutation, n (%) | 0.5053 | Chi-square test | ||
Negative | 67 (38.73%) | 64(36.99%) | ||
Positive | 19 (10.98%) | 23 (13.30%) | ||
IDH1 mutation, n (%) | 0.1211 | Chi-square test | ||
Negative | 81 (46.82%) | 76 (43.93%) | ||
Positive | 5 (2.89%) | 11 (6.36%) | ||
IDH2 mutation, n (%) | 0.0779 | Chi-square test | ||
Negative | 81 (46.82%) | 75 (43.35%) | ||
Positive | 5 (2.89%) | 12 (6.94%) | ||
TET2 mutation, n (%) | 0.7691 | Chi-square test | ||
Negative | 78 (45.09%) | 80 (46.24%) | ||
Positive | 8(4.62%) | 7 (4.05%) | ||
TP53 mutation, n (%) | 0.5926 | Chi-square test | ||
Negative | 80 (46.24%) | 79 (45.67%) | ||
Positive | 6 (3.47%) | 8 (4.62%) | ||
CEBPA mutation, n (%) | 0.7565 | Chi-square test | ||
Negative | 79 (45.66%) | 81 (46.82%) | ||
Positive | 7(4.05%) | 6 (3.47%) | ||
Treatment type, n (%) | 0.2532 | Chi-square test | ||
Chemotherapy | 46 (26.59%) | 54 (31.21%) | ||
Transplant | 40 (23.12%) | 33 (19.08%) |